Pesquisar
Aytu Biopharma Inc
AYTUAdicionar à lista de desejos
2.160USD
+0.010+0.47%
Fechamento 07/01, 16:00（ET）Cotações atrasadas em 15 min
23.18MValor de mercado
PerdaP/L TTM
Mais detalhes de Aytu Biopharma Inc Empresa
Aytu BioPharma, Inc. is a pharmaceutical company focused on commercializing novel therapeutics. The Company's business is focused on its prescription pharmaceutical products sold primarily through third party wholesalers and pharmacies and which primarily consists of two product portfolios. The first consists of two products for the treatment of ADHD: Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets (Adzenys) and Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets. The second consists primarily of Karbinal ER (carbinoxamine maleate extended-release oral suspension), an extended-release first-generation antihistamine suspension containing carbinoxamine indicated to treat numerous allergic conditions, and Poly-Vi-Flor and Tri-Vi-Flor, two complementary prescription fluoride-based supplement product lines containing combinations of fluoride and vitamins in various formulations for infants and children with fluoride deficiency.
Informações de Aytu Biopharma Inc
Código da empresaAYTU
Nome da EmpresaAytu Biopharma Inc
Data de listagemOct 20, 2017
CEODisbrow (Joshua R)
Número de funcionários82
Tipo de títulosOrdinary Share
Fim do ano fiscalOct 20
Endereço7900 E. Union Avenue
CidadeDENVER
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal80237
Telefone17204376580
Sitehttps://aytubio.com/
Código da empresaAYTU
Data de listagemOct 20, 2017
CEODisbrow (Joshua R)
Executivos da empresa Aytu Biopharma Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Jarrett T. (Josh) Disbrow
Mr. Jarrett T. (Josh) Disbrow
Chief Business Officer
Chief Business Officer
61.57K
+52.15%
Mr. Ryan J. Selhorn, CPA
Mr. Ryan J. Selhorn, CPA
Chief Financial Officer, Treasurer, Corporate Secretary
Chief Financial Officer, Treasurer, Corporate Secretary
49.74K
+67.83%
Mr. Greg Pyszczymuka
Mr. Greg Pyszczymuka
Chief Commercial Officer
Chief Commercial Officer
36.10K
+34.05%
Mr. Carl C. Dockery
Mr. Carl C. Dockery
Independent Director
Independent Director
21.15K
+47.28%
Ms. Vivian H. Liu
Ms. Vivian H. Liu
Independent Director
Independent Director
19.82K
+50.44%
Mr. Joshua R. (Josh) Disbrow
Mr. Joshua R. (Josh) Disbrow
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. John A. Donofrio, Jr.
Mr. John A. Donofrio, Jr.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Abhinav (Abi) Jian
Mr. Abhinav (Abi) Jian
Independent Director
Independent Director
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Jarrett T. (Josh) Disbrow
Mr. Jarrett T. (Josh) Disbrow
Chief Business Officer
Chief Business Officer
61.57K
+52.15%
Mr. Ryan J. Selhorn, CPA
Mr. Ryan J. Selhorn, CPA
Chief Financial Officer, Treasurer, Corporate Secretary
Chief Financial Officer, Treasurer, Corporate Secretary
49.74K
+67.83%
Mr. Greg Pyszczymuka
Mr. Greg Pyszczymuka
Chief Commercial Officer
Chief Commercial Officer
36.10K
+34.05%
Mr. Carl C. Dockery
Mr. Carl C. Dockery
Independent Director
Independent Director
21.15K
+47.28%
Ms. Vivian H. Liu
Ms. Vivian H. Liu
Independent Director
Independent Director
19.82K
+50.44%
Mr. Joshua R. (Josh) Disbrow
Mr. Joshua R. (Josh) Disbrow
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Perguntas frequentes
Quem são os cinco principais acionistas de Aytu Biopharma Inc?
Os cinco principais acionistas de Aytu Biopharma Inc são: Mr. Jarrett T. (Josh) Disbrow
Quantas instituições possuem ações da Aytu Biopharma Inc (AYTU)?
Em 2026Q1, 69 instituições possuíam ações da Aytu Biopharma Inc, com valor de mercado aproximado de 3.87M, representando 36.10% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em -493525.00.
Qual é a maior fonte de receita da Aytu Biopharma Inc?
Em 2026Q1, o segmento de negócios ADHD portfolio gerou a maior receita para Aytu Biopharma Inc, totalizando 13.22M e representando 87.15% da receita total.